RESEARCH
Meta-analysis finds ctDNA-negative patients still benefit from more intensive adjuvant treatmentA reconstructed individual patient data meta-analysis of 5,323 ctDNA-negative patients found that more-intensive management was associated with improved outcomes, with a pooled hazard ratio of 0.84 for disease-free survival, though the benefit varied by type of treatment contrast. (Clin Transl Oncol)